Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, B-Cell 2Cytokine Release Syndrome 2Burkitt Lymphoma 2Pancreatic Neoplasms 1Neurotoxicity Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Early Stage Triple Negative ER Low Breast Cancer 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1

Interventions

tocilizumab 2siltuximab 2fludarabine phosphate 2fludarabine 2Interleukin 1 Receptor Antagonist Protein 2Cyclophosphamide 2AP 1903 reagent 2talquetamab 1obinutuzumab 1glofitamab 1axicabtagene ciloleucel 1Oxaliplatin 1Gemcitabine 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × Interleukin 1 Receptor Antagonist Protein × 1 year × Clear all
NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Massachusetts General Hospital

Phase 2 Completed
15 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

NCT06703216 2025-06-15

PACER

Ann & Robert H Lurie Children's Hospital of Chicago

Phase 1/2 Not yet recruiting
24 enrolled
Lymphoid

Cytokine Release Syndrome, Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡